Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9777MR)

This product GTTS-WQ9777MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9777MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6353MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ6777MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ15550MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ9232MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ1444MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ12796MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ2992MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ7945MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-3359609
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW